The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

Aims To estimate the association of smoking status with rates of (i) infection,(ii)
hospitalization,(iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease …

Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …

Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …

Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …

Objective Rheumatoid arthritis (RA) and its treatments are associated with an increased risk
of infection, but it remains unclear whether these factors have an impact on the risk or …

Objectives To investigate outcomes of Coronavirus Disease-2019 (COVID-19) in patients
with rheumatoid arthritis (RA) as compared to the general population. Additionally, outcomes …

As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …

Aim To determine characteristics associated with more severe outcomes in a global registry
of people with systemic lupus erythematosus (SLE) and COVID-19. Methods People with …